GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Sloan Ratio %

LFCR (Lifecore Biomedical) Sloan Ratio % : 0.06% (As of Nov. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Lifecore Biomedical's Sloan Ratio for the quarter that ended in Nov. 2024 was 0.06%.

As of Nov. 2024, Lifecore Biomedical has a Sloan Ratio of 0.06%, indicating the company is in the safe zone and there is no funny business with accruals.


Lifecore Biomedical Sloan Ratio % Historical Data

The historical data trend for Lifecore Biomedical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Sloan Ratio % Chart

Lifecore Biomedical Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 -7.25 -63.37 -30.49 11.87

Lifecore Biomedical Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.78 5.03 11.87 6.21 0.06

Competitive Comparison of Lifecore Biomedical's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Sloan Ratio % falls into.


;
;

Lifecore Biomedical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Lifecore Biomedical's Sloan Ratio for the fiscal year that ended in May. 2024 is calculated as

Sloan Ratio=(Net Income (A: May. 2024 )-Cash Flow from Operations (A: May. 2024 )
-Cash Flow from Investing (A: May. 2024 ))/Total Assets (A: May. 2024 )
=(12.013--0.217
--17.921)/253.96
=11.87%

Lifecore Biomedical's Sloan Ratio for the quarter that ended in Nov. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Nov. 2024 )
=(-14.252-0.071
--14.468)/255.386
=0.06%

Lifecore Biomedical's Net Income for the trailing twelve months (TTM) ended in Nov. 2024 was 15.632 (Feb. 2024 ) + -7.083 (May. 2024 ) + -16.23 (Aug. 2024 ) + -6.571 (Nov. 2024 ) = $-14.3 Mil.
Lifecore Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2024 was -1.816 (Feb. 2024 ) + 8.64 (May. 2024 ) + -0.643 (Aug. 2024 ) + -6.11 (Nov. 2024 ) = $0.1 Mil.
Lifecore Biomedical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Nov. 2024 was -5.969 (Feb. 2024 ) + -2.637 (May. 2024 ) + -3.392 (Aug. 2024 ) + -2.47 (Nov. 2024 ) = $-14.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Nov. 2024, Lifecore Biomedical has a Sloan Ratio of 0.06%, indicating the company is in the safe zone and there is no funny business with accruals.


Lifecore Biomedical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical Business Description

Traded in Other Exchanges
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Executives
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318